4.3 Article

Cladribine transfer into human milk: A case report

Journal

MULTIPLE SCLEROSIS JOURNAL
Volume 27, Issue 5, Pages 799-801

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458520912173

Keywords

Multiple sclerosis; cladribine; human milk; breastfeeding; antimetabolite; relative infant dose

Funding

  1. Innovation Fund of the Federal Joint Committee
  2. Bayer Healthcare Pharmaceuticals
  3. Biogen
  4. Teva Pharma
  5. Merck

Ask authors/readers for more resources

This case report suggests the transfer of cladribine in measurable quantities in human milk, with a relative infant dose of 3.06%. Caution should be advised during lactation.
Background: Cladribine is an antimetabolite used for the treatment of relapsing-remitting multiple sclerosis. At present, there are no data available on its use in breastfeeding mothers and its transfer in human milk. Objective: We present a case of a lactating mother who donated her milk samples to study the transfer of cladribine following a 20-mg oral dose. Methods: Analysis was done using liquid chromatography-mass spectrometry. Results: The relative infant dose calculated in this study was 3.06%. Conclusion: This is the first case report suggesting the transfer of cladribine in human milk in measurable quantities. However, caution should be advised during lactation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available